- |||||||||| LBL-015 / Leads Biolabs
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Phase I/II Clinical Trial of LBL-015 for Injection (clinicaltrials.gov) - Oct 28, 2024
P1/2, N=25, Completed,
Recruiting --> Completed | N=202 --> 25 | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Oct 2024 --> Dec 2023
- |||||||||| LBL-015 / Leads Biolabs
Trial primary completion date, Metastases: Phase I/II Clinical Trial of LBL-015 for Injection (clinicaltrials.gov) - Nov 9, 2023
P1/2, N=202, Recruiting,
signaling pathway deregulated or activated tumors such as RCC, pancreatic cancer, etc. should be further explored. Trial primary completion date: Oct 2023 --> Oct 2024
- |||||||||| LBL-015 / Leads Biolabs
Enrollment open, Metastases: Phase I/II Clinical Trial of LBL-015 for Injection (clinicaltrials.gov) - Dec 10, 2021
P1/2, N=202, Recruiting,
Trial primary completion date: Oct 2023 --> Oct 2024 Not yet recruiting --> Recruiting
- |||||||||| LBL-015 / Leads Biolabs
[VIRTUAL] LBL-015, a novel anti-PD-1 fused with TGF-βRII, shows a great anti-tumor activity in a mouse MC38 model () - Mar 11, 2021 - Abstract #AACR2021AACR_2983;
In vitro LBL-015 could block PD-1-PD-L1 interaction, recovering NFAT reporter gene signal, with EC50 of 0.1565 nM, which was much more potent than M7824 (EC50 of 0.5412 nM). LBL-015, an anti-PD-1 and TGF-β bispecific fusion protein was shown a great synergetic anti-tumor efficacy in vitro to antagonize both tumor immune evasion and aberrant microenvironment induced by PD-1 and TGF-β1, also in a mouse tumor model, LBL-015 strongly inhibited tumor growth in a dose dependent manner, hence a promising bispecific fusion protein for further clinical development.
|
